Dizal (Jiangsu) Pharmaceutical Valuation
Is 688192 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688192 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 688192 (CN¥48.38) is trading below our estimate of fair value (CN¥165.15)
Significantly Below Fair Value: 688192 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688192?
Key metric: As 688192 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 688192's PB Ratio? | |
|---|---|
| PB Ratio | 46.9x |
| Book | CN¥428.43m |
| Market Cap | CN¥20.11b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 51.9x |
| Enterprise Value/EBITDA | -22.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 688192's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.9x | ||
688062 Mabwell (Shanghai) Bioscience | 5.1x | 58.2% | CN¥9.7b |
688382 InventisBio | 3.5x | 58.4% | CN¥6.0b |
688266 Suzhou Zelgen BiopharmaceuticalsLtd | 13.9x | 125.6% | CN¥18.5b |
688278 Xiamen Amoytop Biotech | 13.2x | 32.0% | CN¥30.3b |
688192 Dizal (Jiangsu) Pharmaceutical | 46.9x | 58.9% | CN¥20.1b |
Price-To-Book vs Peers: 688192 is expensive based on its Price-To-Book Ratio (46.9x) compared to the peer average (9x).
Price to Book Ratio vs Industry
How does 688192's PB Ratio compare vs other companies in the CN Biotechs Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 688192 is expensive based on its Price-To-Book Ratio (46.9x) compared to the CN Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is 688192's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 46.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 688192's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥48.38 | CN¥56.00 +15.8% | 3.6% | CN¥58.00 | CN¥54.00 | n/a | 2 |
| Apr ’25 | CN¥43.60 | CN¥52.16 +19.6% | 3.5% | CN¥54.00 | CN¥50.31 | n/a | 2 |
| Mar ’25 | CN¥37.25 | CN¥52.16 +40.0% | 3.5% | CN¥54.00 | CN¥50.31 | n/a | 2 |
| Feb ’25 | CN¥32.17 | CN¥52.16 +62.1% | 3.5% | CN¥54.00 | CN¥50.31 | n/a | 2 |
| Jan ’25 | CN¥47.85 | CN¥57.73 +20.7% | 13.9% | CN¥68.89 | CN¥50.31 | n/a | 3 |
| Dec ’24 | CN¥46.65 | CN¥57.73 +23.8% | 13.9% | CN¥68.89 | CN¥50.31 | n/a | 3 |
| Nov ’24 | CN¥42.76 | CN¥57.73 +35.0% | 13.9% | CN¥68.89 | CN¥50.31 | CN¥48.14 | 3 |
| Oct ’24 | CN¥35.48 | CN¥57.73 +62.7% | 13.9% | CN¥68.89 | CN¥50.31 | CN¥43.82 | 3 |
| Sep ’24 | CN¥32.71 | CN¥57.73 +76.5% | 13.9% | CN¥68.89 | CN¥50.31 | CN¥37.65 | 3 |
| Aug ’24 | CN¥36.09 | CN¥56.42 +56.3% | 13.0% | CN¥68.89 | CN¥50.31 | CN¥39.34 | 4 |
| Jul ’24 | CN¥34.70 | CN¥56.42 +62.6% | 13.0% | CN¥68.89 | CN¥50.31 | CN¥35.94 | 4 |
| Jun ’24 | CN¥44.87 | CN¥56.42 +25.7% | 13.0% | CN¥68.89 | CN¥50.31 | CN¥39.45 | 4 |
| May ’24 | CN¥53.55 | CN¥51.40 -4.0% | 2.1% | CN¥52.48 | CN¥50.31 | CN¥45.05 | 2 |
| Apr ’24 | CN¥42.37 | CN¥51.40 +21.3% | 2.1% | CN¥52.48 | CN¥50.31 | CN¥43.60 | 2 |
| Mar ’24 | n/a | CN¥51.40 0% | 2.1% | CN¥52.48 | CN¥50.31 | CN¥37.25 | 2 |
| Feb ’24 | n/a | CN¥51.40 0% | 2.1% | CN¥52.48 | CN¥50.31 | CN¥32.17 | 2 |
| Jan ’24 | n/a | CN¥50.63 0% | 3.7% | CN¥52.48 | CN¥48.78 | CN¥47.85 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥51.8b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥32.19
7D
1.8%
1Y
12.2%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.7b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥20.87
7D
-5.5%
1Y
11.1%
Dong-E-E-JiaoLtd
CN¥37.4b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥58.18
7D
-0.4%
1Y
15.5%